PROVO, Utah, Dec. 18 /PRNewswire-FirstCall/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) introduced the new ageLOC Future Serumto more than 10,000 sales representatives at its launch event in Japan. Japanese distributors were eager to be in the first market to fully launch one of the company's new ageLOC skin care products that targets the sources
"We continue to believe that ageLOC will be the biggest global product launch in Nu Skin history and are pleased to begin the roll out in Japan," said Truman Hunt, Nu Skin president and chief executive officer. "We are committed to fueling the positive trends we are seeing in Japan and believe that the introduction of ageLOC will help in generating distributor enthusiasm in this important market. Our proprietary ageLOC products enable our sales representatives to take advantage of the accelerating growth in the anti-aging industry, which is expected to grow by 73 percent in Japan by 2015. We'll continue the global roll out of ageLOC next month as we launch new ageLOC skin care products in the United States, Europe and Latin America."
ageLOC Product Introduction
ageLOC Future Serum, is an anti-aging serum that integrates the most advanced science and technology from Nu Skin to preserve the look of youth and reduce the appearance of aging. This product combines the benefits of many different anti-aging products and is clinically proven to reveal younger looking skin in eight key ways beginning in just seven days.
New SAB Member Introduced
Nu Skin Japan also announced Makoto Kuro-O, M.D., Ph.D., associate professor of pathology at the University of Texas Southwestern Medical Center, as a new member of its Anti-Aging Scientific Advisory Board. Dr. Kuro-O will also serve as the chairman of the Nu Skin Japan Scientific Advisory Board, providing his insights on gene-based anti-aging science.
"We are honored to welcome Dr. Kuro-O to the Nu Skin Anti-Aging Scientific Advisory Board and believe that our collaboration with Dr. Kuro-O will add even more fuel to our scientific efforts to target the sources of aging," said Joseph Chang, Ph.D., Nu Skin chief scientific officer and executive vice president of product development. "Dr. Kuro-O is a scientific luminary from Japan who has spent much of his career studying the genetic basis of aging and has garnered significant attention in the scientific community related to his identification of an important gene that could play a critical role in aging. This important work will add to the further understanding of the molecular mechanism by which certain proteins regulate aging."
For 25 years, Nu Skin Enterprises, Inc. has been demonstrating its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. Nu Skin's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC™ science that addresses aging at its source. The company's anti-aging product portfolio features the new ageLOC daily skin care system and Future Serum, as well as the Galvanic Spa® System II, Tru Face® Essence Ultra, LifePak® Nano and the g3 nutrition beverage. A global direct selling company, Nu Skin operates in 48 markets worldwide and has more than 750,000 independent sales representatives. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com.
Please note: This press release, contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company's current expectations and beliefs, including, among other things: (i) management's expectations regarding the company's ageLOC™ skin-care product line; (ii) management's expectations and beliefs regarding Japan; and (iii) management's expectations and beliefs regarding Dr. Kuro-o. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to: (a) any failure of the company's ageLOC™ skin-care product line to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis; (b) regulatory risks associated with the company's products, including any risks that unauthorized product claims made by distributors would cause such products to be classified as drugs; and (c) risks associated with our operations in Japan, including increased regulatory scrutiny of the direct selling industry, any adverse publicity related to the company or others in the direct selling industry, continued competitive pressures in the market, fluctuations in the Japanese yen and difficult economic conditions. The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 27, 2009 and Quarterly Reports on Form 10-Q filed on May 8, 2009, August 7, 2009 and November 9, 2009. The forward-looking statements set forth the company's beliefs as of the date of this release, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
SOURCE Nu Skin Enterprises, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All